INFORMAZIONI SU QUESTO EPISODIO
When does a neuroendocrine tumor warrant a second look? Join Dr. Nisha Mohindra and Dr. Rahul Aggarwal as they explore the clinical, imaging, and pathologic clues that distinguish neuroendocrine tumors from neuroendocrine carcinomas. Learn how multidisciplinary assessment, pathology review, and repeat biopsy can help resolve diagnostic uncertainty in challenging cases.
Visit https://www.atpointofcare.com/library/2759.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.
This podcast is powered by Pinecast.
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di Hematology / Oncology @Point of Care Podcasts.
ALTRI EPISODI IN QUESTO PODCAST
This expert-led podcast explores practical treatment selection in the evolving perioperative landscape for muscle-invasive bladder cancer. Faculty will discuss how to assess treatment eligibility, navigate immunotherapy-based and antibody-drug conjugate–based options, and coordinate care across spe…
Stay ahead of evolving endocrine resistance in HR-positive, HER2-negative advanced breast cancer. Discover how ESR1 mutations are reshaping treatment decisions, and explore expert perspectives on mutation testing, oral SERDs, and emerging serial monitoring strategies that may help identify resistan…
This expert-led podcast explores the rapidly evolving perioperative treatment landscape in muscle-invasive bladder cancer. Faculty will discuss pivotal data from NIAGARA, KEYNOTE-905, and KEYNOTE-B15, and consider how recent advances are expanding systemic treatment options, including for patients …
This final episode of a three-part expert-led podcast series explores the emerging toxicity landscape as immunotherapy- and antibody-drug conjugate–based regimens enter the treatment of muscle-invasive bladder cancer. Faculty will discuss the mechanistic basis for these side effects, practical moni…
Explore the evolving role of oral SERDs in HR-positive, HER2-negative advanced breast cancer. Hear expert perspectives on ESR1 mutation testing, treatment selection and sequencing, emerging combination strategies, circulating tumor DNA (ctDNA) monitoring, and safety considerations that may inform i…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da @Point of Care, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
